Version history

{
  "session_id": "sess_b7f886d9-da3f-4e0d-a8a8-9c262e268796_task_66f1207e_recon",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics as proximal driver in m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra\",\n      \"description\": \"m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics should produce a measurable proximal phenotype before late disease pathology. The decisive test is dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays.\",\n      \"target_gene\": \"m6A\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.67,\n        \"therapeutic_potential\": 0.64,\n        \"mechanistic_plausibility\": 0.7,\n        \"druggability\": 0.54,\n        \"safety_profile\": 0.52,\n        \"competitive_landscape\": 0.58,\n        \"data_availability\": 0.66,\n        \"reproducibility\": 0.61\n      },\n      \"composite_score\": 0.626,\n      \"evidence_for\": [\n        {\n          \"claim\": \"Multi-omics analysis implicated m6A modification in PD risk but the causal downstream mechanism on alpha-synuclein biology was not established.\",\n          \"doi\": \"10.1038/s41380-024-02574-w\",\n          \"source\": \"Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"global m6A manipulation can create broad toxicity and indirect proteostasis effects\",\n          \"doi\": \"10.1038/s41380-024-02574-w\",\n          \"source\": \"Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease\"\n        }\n      ]\n    },\n    {\n      \"title\": \"Cell-state stratification is required to resolve m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra\",\n      \"description\": \"The question is likely underpowered or misleading unless analyses preserve the key strata: m6A, RNA, N6-, alpha-synuclein. Averaging across these strata could convert a causal subpopulation effect into a weak association.\",\n      \"target_gene\": \"RNA\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.58,\n        \"novelty\": 0.64,\n        \"feasibility\": 0.73,\n        \"therapeutic_potential\": 0.55,\n        \"mechanistic_plausibility\": 0.65,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.62,\n        \"competitive_landscape\": 0.56,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.612,\n      \"evidence_for\": [\n        {\n          \"claim\": \"The open question explicitly depends on cell-type, region, or molecular-state resolution.\",\n          \"doi\": \"10.1038/s41380-024-02574-w\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"Stratified effects may reflect sampling or annotation artifacts rather than mechanism.\",\n          \"doi\": \"10.1038/s41380-024-02574-w\"\n        }\n      ]\n    },\n    {\n      \"title\": \"Perturbation-first validation should precede therapeutic claims for m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra\",\n      \"description\": \"The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.\",\n      \"target_gene\": \"N6-\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.6,\n        \"feasibility\": 0.76,\n        \"therapeutic_potential\": 0.57,\n        \"mechanistic_plausibility\": 0.63,\n        \"druggability\": 0.48,\n        \"safety_profile\": 0.6,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.68,\n        \"reproducibility\": 0.66\n      },\n      \"composite_score\": 0.608,\n      \"evidence_for\": [\n        {\n          \"claim\": \"The proposed priority experiment is concrete: dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays\",\n          \"doi\": \"10.1038/s41380-024-02574-w\"\n        }\n      ],\n      \"evidence_against\": [\n        {\n          \"claim\": \"Therapeutic tractability is not established by the current source evidence.\",\n          \"doi\": \"10.1038/s41380-024-02574-w\"\n        }\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"b7f886d9-da3f-4e0d-a8a8-9c262e268796\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"m6A\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_reconstructs_evidence_for\"\n    },\n    {\n      \"source_id\": \"b7f886d9-da3f-4e0d-a8a8-9c262e268796\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"RNA\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_reconstructs_evidence_for\"\n    },\n    {\n      \"source_id\": \"b7f886d9-da3f-4e0d-a8a8-9c262e268796\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"N6-\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_reconstructs_evidence_for\"\n    },\n    {\n      \"source_id\": \"b7f886d9-da3f-4e0d-a8a8-9c262e268796\",\n      \"source_type\": \"analysis\",\n      \"target_id\": \"alpha-synuclein\",\n      \"target_type\": \"entity\",\n      \"relation\": \"debate_reconstructs_evidence_for\"\n    }\n  ],\n  \"synthesis_summary\": \"Consensus: m6A RNA Modification and Alpha-Synuclein Aggregation in Substantia Nigra is a valid debate target because it is anchored to Integration of multi-omics summary data reveals the role of N6-methyladenosine in Parkinson's disease and asks a falsifiable question about m6A-dependent control of alpha-synuclein transcript fate and aggregation kinetics. Dissent: the source evidence does not yet prove causality, and global m6A manipulation can create broad toxicity and indirect proteostasis effects. The next step is dopaminergic-neuron perturbation of m6A writers/erasers/readers with RNA stability, translation, and Lewy-body-like aggregation assays.\"\n}",
  "tokens_used": "1476",
  "persona_id": "persona-synthesizer"
}